Početna stranica038290 • KOSDAQ
add
Macrogen Inc
Preth. zaklj. cijena
16.450,00 ₩
Dnevni raspon
16.310,00 ₩ - 17.090,00 ₩
Godišnji raspon
14.920,00 ₩ - 26.700,00 ₩
Tržišna kapitalizacija
173,35 mlr. KRW
Prosječna količina
63,24 tis.
P/E omjer
-
Prinos dividende
1,82 %
Glavno tržište vrijednosnica
KOSDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (KRW) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 33,00 mlr. | 2,20 % |
Operativni troškovi | 13,80 mlr. | 4,68 % |
Neto dohodak | −3,18 mlr. | −60,92 % |
Neto profitabilnost | −9,64 | −57,52 % |
Zarada po dionici | — | — |
EBITDA | 2,21 mlr. | 47,21 % |
Efektivna porezna stopa | 1,20 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (KRW) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 24,60 mlr. | 8,61 % |
Ukupna imovina | 274,19 mlr. | 3,79 % |
Ukupne obveze | 124,82 mlr. | 40,99 % |
Ukupni kapital | 149,37 mlr. | — |
Dionice u optjecaju | 9,97 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,11 | — |
Povrat imovine | −0,54 % | — |
Povrat kapitala | −0,70 % | — |
Tok novca
Neto promjena novca
| (KRW) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −3,18 mlr. | −60,92 % |
Gotovina od poslovanja | −2,08 mlr. | 50,99 % |
Gotovina iz ulaganja | −9,57 mlr. | −22,48 % |
Gotovina iz financiranja | 6,73 mlr. | 594,06 % |
Neto promjena novca | −4,51 mlr. | 58,99 % |
Slobodan tok novca | −10,07 mlr. | 35,34 % |
Više
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Glavni izvršni direktor
Osnovano
5. lip 1997.
Web-lokacija
Zaposlenici
519
